Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.48 |
| ▸ | PRKDC | P78527 | 11/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555162 | 0.86 | PIK3CA (0.51) | PIK3CAPRKDCPIK3CGBRDTPIK3CD | |
| SCHEMBL4105698 | 0.84 | PIK3CA (0.63) | PIK3CAPRKDCPIK3CGBRDTPIK3CD | |
| SCHEMBL3295818 | 0.82 | PRKDC (0.72) | PIK3CAPRKDCPIK3CGBRDTPIK3CD | |
| SCHEMBL3554352 | 0.82 | PIK3CA (0.51) | PIK3CAPRKDCPIK3CGPIK3CDPIK3CB | |
| SCHEMBL3628127 | 0.79 | PRKDC (0.72) | PIK3CAPRKDCPIK3CGPIK3CBMTOR | |
| SCHEMBL4116939 | 0.78 | PRKDC (0.72) | PRKDC | |
| SCHEMBL3715525 | 0.77 | PIK3CA (0.51) | PIK3CAPRKDCPIK3CGBRDTPIK3CD | |
| SCHEMBL13403505 | 0.74 | PRKDC (0.72) | PIK3CAPRKDCPIK3CDPIK3CBMTOR | |
| SCHEMBL909904 | 0.73 | PIK3CG (0.71) | PIK3CAPRKDCPIK3CGBRDTPIK3CD | |
| SCHEMBL4809435 | 0.73 | PIK3CA (0.67) | PIK3CAPRKDCPIK3CGBRDTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696203-B2 | DNA-PK inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-13 | — | — | US | disclosed |
| EP-1869021-A1 | DNA-PK INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| WO-2006109081-A1 | DNA-PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264427-A1 | 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents | POLK, DCK, POLN | PIK3CA 1723/4885PRKDC 33/4885PIK3CG 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.